Recently, by using a T cell receptor α (TCR α) repertoire-deficient mouse model, Zhang et al. observed that CD4+ TRM cells could initiate a potent anti-tumor immune response associated with a significant inhibition of both melanoma and BC progression. Here, CD4 is linked to neoplasm.